U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2F.Zn.4H2O
Molecular Weight 175.467
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC FLUORIDE TETRAHYDRATE

SMILES

O.O.O.O.[F-].[F-].[Zn++]

InChI

InChIKey=OEUUYPRXVRBIFO-UHFFFAOYSA-L
InChI=1S/2FH.4H2O.Zn/h2*1H;4*1H2;/q;;;;;;+2/p-2

HIDE SMILES / InChI
Molecular Formula FH
Molecular Weight 20.0063
Charge 0
Count
MOL RATIO 2 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
MOL RATIO 4 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

There is no available information related any biological and pharmaceutical application of ammonium tetrachlorozincate.

CNS Activity

CNS Active
3,913

Originator

Smithson, R.
38

Approval Year

1921
1,467

Targets

Primary TargetPharmacologyConditionPotency
Streptococcus mutans
41
Inhibitor
8,297
respiratory burst
39
Activator
1,430
transformed cell apoptotic process
108
Activator
1,430
Methotrexate
38
Hydrolytic Enzyme
38
ultraviolet B-induced damage
38
Interacts
323
T cell mediated immunity
40
Activator
1,430
Zinc transporter ZIP1
38
Binding Agent
1,064
Zinc transporter ZIP2
38
Binding Agent
1,064

Conditions

ConditionModalityTargetsHighest PhaseProduct
Caries
43
 Preventing
Basic research
Unknown
Ulcerative colitis
123
 Primary
Approved
8,429
CORTROPHIN-ZINC
Zinc deficiency
39
 Primary
Preclinical
Unknown
Acute myeloid leukemia
136
 Primary
Basic research
Unknown
Breast cancer
434
 Primary
Basic research
Unknown
Renal insufficiency
40
 Secondary
Approved
8,429
VORAXAZE
Diaper dermatitis
38
 Primary
Approved
8,429
VUSION
Poison Ivy dermatitis
38
 Primary
Approved
8,429
ZINC OXIDE
Gastrointestinal disorders
95
 Primary
Approved
8,429
ZINC SULFATE
Mucositis
39
 Primary
Phase III
656
ZINC SULFATE
Dysgeusia
38
 Primary
Phase III
656
ZINC SULFATE

PubMed

Patents

04005147
106
04090844
38
04134847
38
04292237
38
04376079
39
04377675
40
04404196
40
04565693
38
04670586
38
04740363
38
04743435
42
04904401
38
04950702
42
05064815
38
05149745
38
05442047
38
05539121
38
05646324
38
05773011
38
05911978
38
06140331
38
06303833
38
06706904
38
07375243
38
07585885
44
07799339
38
07959530
39
08258190
38
20060128799
38
20060270867
38
20070213331
40
20070249787
39
20080274173
38
20090092554
38
20100048844
38
20100117110
38
20100324259
38
7632959
38
CN105567322
38
EP0119068A1
38
US1767667
38
US20070265374
38
US2522537
38
US2537262
38
US3248354
38
US3453072
38
US3790469
38
US6853140
38

Sample Use Guides

In Vivo Use Guide
single intravenous injection of 50 Units per kg
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
SQ7815WXFB
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966